RESUMEN
Introduction: Despite the frequently coexistence and prominent negative effect of depression in Parkinson’s disease, there is currently no evidence-based standard of care. Objective: The purpose of this study was to examine the efficacy and tolerability of individually administered selective serotonin reuptake inhibitor (SSRI) - escitalopram, relative to clinical monitoring (with no new treatment), for depression in this medical population. Method: In this retrospective open label analysis of 28 depressed (based on ICD-10 criteria and Mini International Neuropsychiatric Interview) patients with Parkinson’s disease were treated with escitalopram 10-20 mg/d for duration of 8 weeks. The Hospital Anxiety and Depression Scale (HADS) depression subscale score and Clinical Global Impression-Improvement (CGI-I) score was the primary outcome. Assessments were completed at baseline, 4 (midpoint) and 8 (end of treatment) weeks of follow-up evaluation. Results: Although treatment was well tolerated and correlated with a significant decrease in HADS and CGI score, response and remission rates were 43.4% and 57.2%, respectively. Conclusions: Escitalopram may be a viable approach for the treatment of depression in Parkinson’s disease. Further research is needed to replicate and extend these findings.